ArticleCureus2025
Impact of Inflammatory Bowel Disease on Quality of Life and Work Productivity in Patients Under Treatment.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder that often emerges in early adulthood, coinciding with peak occupational years. Despite therapeutic progress, IBD continues to impair health-related quality of life (HRQoL) and work capacity. This study aimed to assess its impact on quality of life and work productivity compared with healthy controls. Methodology This cross-sectional, observational study included 371 patients with IBD (CD: 59.8%; UC: 40.2%) and 371 age- and gender-matched healthy controls, recruited from two tertiary hospitals. Clinical, endoscopic, and demographic data were collected, including disease duration, treatment regimen, disease activity, and the presence of extraintestinal manifestations. HRQoL was assessed using the EuroQol 5 Dimensions 3 Levels (EQ-5D-3L), and work productivity was assessed using the Work Productivity and Activity Impairment (WPAI) questionnaire. Predictive models were implemented using categorical regression with optimal scaling. Results Across all dimensions of the EQ-5D-3L and WPAI, patients with IBD reported greater impairment than healthy controls (p < 0.001). Multivariable models identified physically demanding occupation as the strongest predictor of impaired patient-reported outcomes, with extraintestinal manifestations, age, gender, and disease duration contributing variably across domains (all p < 0.05). CD was independently associated with limitations in usual activities (p = 0.007). Both the Harvey-Bradshaw Index (p < 0.001) and Partial Mayo Score (p < 0.001) correlated negatively with health state and activity impairment. Conclusions IBD patients under treatment continue to experience significant impairments in HRQoL and work productivity compared with healthy controls. Physically demanding occupation, extraintestinal manifestations, and CD emerged as key determinants of impaired outcomes in IBD, highlighting the need for integrated management strategies addressing occupational and systemic disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.